PTEN

                                       (Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase)

  • Alias                                 (According to NCBI)

 
  • BZS 
  • MGC11227
  • MHAM
  • MMAC1
  • PTEN1
  • TEP1
  • Bannayan-Zonana syndrome
  • Human mutated in multiple advanced cancers protein (MMAC1) mRNA, complete cds
  • MMAC1 phosphatase and tension homolog deleted on chromosome 10
  • multiple hamartoma (Cowden syndrome)
  • mutated in multiple advanced cancers 1 
  • phosphatase and tensin homolog (mutated in multiple advanced cancers 1) 
  • Phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase PTEN (EC 3.1.3.67) (Mutated in multiple advanced cancers 1).

  •  This gene was identified as a tumor suppressor that is mutated in a large number of cancers at high frequency. The protein encoded this gene is a phosphatidylinositol-3,4,5-trisphosphate 3-phosphatase. It contains a tension like domain as well as a catalytic domain similar to that of the dual specificity protein tyrosine phosphatases. Unlike most of the protein tyrosine phosphatases, this protein preferentially dephosphorylates phosphoinositide substrates. It negatively regulates intracellular levels of phosphatidylinositol-3,4,5-trisphosphate in cells and functions as a tumor suppressor by negatively regulating AKT/PKB signaling pathway.
  • Location:10q23.3
  • Orientation: Plus strand
  • Size:102,936 bases
  • 9 Exons
  • DNA Sequence: NT_030059

  • CGH (10q23.3):  Losses (%) - 8.8   Gain (%)  0.0   Amplifications  0.0
  • Mutations and SNPs (According to HGMD and SNP)
  • m-RNA                       (According to NCBI and CGAP)

 
  • Size:403 amino acids; 47166 Da
  • Catalytic activity:Phosphatidylinositol-3,4,5-trisphosphate + H(2)O = phosphatidylinositol-4,5-bisphosphate + phosphate.
  • Protein domains:

                                                  
  • Pathways and interactions (According to BioCarta, DIP)
   
  • Clinical                            (According to OMIM, PubMed)